New Treatment for Pancreatic Cancer: A Dual Inhibitor

Understanding Pancreatic Cancer

Pancreatic cancer is recognized as one of the most aggressive and deadly forms of cancer. It ranks as the fourth-leading cause of cancer-related deaths in the United States, with a five-year survival rate of less than 7%. According to the American Cancer Society, nearly 55,000 Americans were diagnosed with pancreatic cancer in 2018, resulting in approximately 44,000 fatalities. The incidence of this cancer type continues to rise, with projections indicating that new cases and deaths could more than double by 2030.

Challenges in Diagnosis and Treatment

One of the significant challenges with pancreatic cancer is that it often presents no early signs or symptoms, complicating timely diagnosis and treatment. Compared to other cancers, pancreatic cancer exhibits a high resistance to standard chemotherapy. Furthermore, only about 20% of patients qualify for surgical resection, as the cancer is frequently diagnosed after it has metastasized.

Current Treatment Landscape

At present, a limited number of combination chemotherapies have received approval from the Food and Drug Administration (FDA). However, many of these treatments have not demonstrated long-term benefits for patients with advanced disease who cannot undergo surgery.

Breakthrough Research Findings

In a recent study published in the journal Cancer Research, researchers from the University of Houston presented promising findings regarding a new treatment for pancreatic cancer. This innovative drug, named MA242, shows potential in enhancing the specificity and efficiency of tumor eradication by targeting two major pathways associated with the disease.

Future Directions for Treatment

The development of this dual inhibitor represents a significant advancement in the treatment of pancreatic cancer. Further research is necessary to explore the potential of MA242 as a lead compound for both prevention and treatment of this challenging disease.

Author and Reference

Written by Man-tik Choy, Ph.D.
Reference: Fickman, L. (2018, September 11). Drug for Pancreatic Cancer Developed by College of Pharmacy Researchers. Retrieved from http://www.uh.edu/news-events/stories/2018/september-2018/091118-pancreatic-cancer-drug.php